NUS

Nu Skin Reaches 800 Million Meals Purchased and Donated in its Fight Against Child Malnutrition

Retrieved on: 
Wednesday, January 11, 2023
NTC, NYSE, Nu Skin Enterprises, Food, NUS, Vitamer, Beauty, Toy

PROVO, Utah, Jan. 11, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS), a leading beauty and wellness company, today announced it has reached the milestone of providing 800 million meals for children since 2002 through its Nourish the Children (NTC) initiative.

Key Points: 
  • PROVO, Utah, Jan. 11, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS), a leading beauty and wellness company, today announced it has reached the milestone of providing 800 million meals for children since 2002 through its Nourish the Children (NTC) initiative.
  • Malnourished children in more than 65 countries around the world have been fed VitaMeal,* a nutrient-dense food, from one of NTC's third-party charity partners after Nu Skin sales leaders, customers or employees purchase and donate bags of food.
  • "When we started this initiative more than 20 years ago, we never imagined the sustained impact it would have on millions of malnourished children around the world," said Steven J. Lund, Nu Skin executive chairman of the board and executive director of Nourish the Children.
  • "Our combined efforts have impacted the lives of millions, and we look forward to our continued impact on millions more."

Nu Skin Enterprises to Announce Fourth Quarter and 2022 Financial Results

Retrieved on: 
Monday, January 9, 2023
NYSE, NUS, Skin, Nu Skin Enterprises, Webcast, Video game, Online shopping, Risk management

PROVO, Utah, Jan. 9, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release fourth quarter and full year 2022 results after the market closes on Wednesday, Feb. 15.

Key Points: 
  • PROVO, Utah, Jan. 9, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release fourth quarter and full year 2022 results after the market closes on Wednesday, Feb. 15.
  • The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m.
  • During the call, management will discuss recent results and upcoming business initiatives.
  • The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com.

ShareInvestor Group's S$30M Merger with InvestingNote Adds Vitality to Singapore's Retail Investing Scene

Retrieved on: 
Wednesday, January 4, 2023
Knowledge, Information technology, Management, IPO, ASEAN, Ministry, Gen, Stockbroker, NUS, Millennials, Generation Z, Growth, Internet, Singapore Exchange, MOE, Advertising, Mace Head Atmospheric Research Station, Immersion, Financial services, Tutoring, Security (finance), Generation X, Research

The deal terms for the merger values the combined Group at more than S$30 million.

Key Points: 
  • The deal terms for the merger values the combined Group at more than S$30 million.
  • Shanison's belief that financial literacy should be fun and profitable has powered Investing Note to be the largest social network for young retail investors in both Singapore and Malaysia.
  • Mr Christopher Lee, CEO, ShareInvestor Group said: "The merger with InvestingNote is a natural progression for ShareInvestor given our long and synergistic relationship.
  • The merger between ShareInvestor and InvestingNote will combine talents and capabilities of both platforms and broaden their reach to investors in the region.

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

Retrieved on: 
Tuesday, December 6, 2022
National University of Singapore, Applied science, Biocatalysis, Interdisciplinarity, Agency, Disease, Associate, Biology, SIT, Assistant, EDB, D, Robotics, National university, Partnership, Carbon, GSK, Sustainability, Learning, Ecosystem, 2025, NUS, Science and Engineering Research Council, Vaccine, Environment, Agency for Science, Technology and Research, COVID-19, Innovation, Machine learning, Shannon Applied Biotechnology Centre, Biomedicine, Enablement, NTU, Singapore Institute of Technology, Nanyang Technological University, Pandemic, Committee on the Office of the Deputy Prime Minister, PIPS, Analytics, A*STAR, Biomedical Research Council, Framework Programmes for Research and Technological Development, Pharmaceutical industry, Management, Fine chemical, Sanofi, Research, Science, Takeda

BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.

Key Points: 
  • BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.
  • Amid the COVID-19 pandemic, biologics and vaccines played a critical role globally in preventing severe disease and saving lives.
  • The consortium ultimately aims to make Singapore's biologics manufacturing capabilities best-in-class and well-positioned for the introduction of new products and novel manufacturing technologies.
  • "Riding on the success of PIPS, BioPIPS aims to enhance Singapore's innovation capabilities in biologics and vaccines manufacturing by leveraging the strengths of our leading pharmaceutical companies and institutes of higher learning.

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Retrieved on: 
Monday, December 12, 2022
Life, Gates Cambridge Scholarship, Quality of life, Oropharyngeal cancer, National university, Security (finance), Lymphatic system, Doxorubicin, CSI, DNA, Cancer, Mucositis, Gene expression, ASH, NUS, MD, National University of Singapore, Immanuel Congregation (CSI), Singapore, Gene, Research, Society, Apoptosis, Therapy, DDR, COVID-19, Patient, Drug resistance, Pharmaceutical industry, Vaccine

WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).

Key Points: 
  • WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).
  • Monopar has made the poster available on its website at the following link: https://www.monopartx.com/pipeline/mnpr-202 .
  • MNPR-202 is a promising DNA Damaging Response (DDR) drug candidate, and analog of doxorubicin.
  • Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Nu Skin Scientists Present Studies at Annual Meeting of the Society of Cosmetic Chemists

Retrieved on: 
Monday, December 12, 2022
Society, Publication, Alpha-Tocopherol, Neurodegeneration, Research and development, Cellulite, Development, Nu Skin Enterprises, Glycerol, Beauty, Society of Cosmetic Chemists, Science, Collection, Skin, NYSE, NUS, Cosmetics, Triglyceride, Growth, Multimedia, Nature, Education, Health, Pharmaceutical industry, Research, Pacific Ocean

PROVO, Utah, Dec. 12, 2022 /PRNewswire/ -- Nu Skin Enterprises (NYSE: NUS), a leader in beauty and wellness, today announced its participation in this week's 76th Annual Scientific Meeting & Showcase of the Society of Cosmetic Chemists in Los Angeles.

Key Points: 
  • PROVO, Utah, Dec. 12, 2022 /PRNewswire/ -- Nu Skin Enterprises (NYSE: NUS), a leader in beauty and wellness, today announced its participation in this week's 76th Annual Scientific Meeting & Showcase of the Society of Cosmetic Chemists in Los Angeles.
  • Scientists associated with Nu Skin are involved in several sessions of the annual meeting:
    Several Nu Skin scientists are presenting a scientific poster on work that could have an impact on the accumulation and/or visibility of cellulite.
  • Nu Skin Vice President of Research and Development Dr. Helen Knaggs is moderating today's panel on the Future of Beauty.
  • "Each year, Nu Skin scientists are conducting significant research that is published in scientific journals and presented at conferences all around the world," said Nu Skin Vice President of Research and Development Dr. Helen Knaggs.

Nu Skin's ageLOC LumiSpa iO Named a "New Product of the Year" in the 2022 BIG Awards

Retrieved on: 
Tuesday, November 29, 2022
Organization, Growth, Skin, Science, Nature, Cosmetics, Nu Skin Enterprises, Multimedia, Life, Education, NUS, Skin care, NYSE, Health, Collection, BIG, Beauty, Business, Video game, Pacific Ocean

PROVO, Utah, Nov. 29, 2022 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS), a global beauty and wellness leader,today announced that Business Intelligence Group (BIG) named ageLOC LumiSpa iOa winner of a 2022 "New Product of the Year" award.

Key Points: 
  • PROVO, Utah, Nov. 29, 2022 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS), a global beauty and wellness leader,today announced that Business Intelligence Group (BIG) named ageLOC LumiSpa iOa winner of a 2022 "New Product of the Year" award.
  • "The new LumiSpa iO connects to the Nu Skin Vera app to offer customized treatment options, intelligent coaching, a selfie timeline, skincare routine tracking and more."
  • Organizations from across the world submitted their recent innovations for consideration in the 2022 BIG Awards for Business.
  • The Nu Skin Force for Good Foundation also strives to improve children's health, education and economic circumstances throughout the world.

Nexstar Media Group and PBF Energy Set to Join S&P MidCap 400; Sabre and Nu Skin Enterprises to Join S&P SmallCap 600

Retrieved on: 
Monday, November 28, 2022
Sabre, NYCB, Nu Skin Enterprises, SABR, FBC, PBF Energy, NXST, Flagstar Bank, New York Community Bank, NUS, NYSE, PBF, NASD, Sabre Corporation

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the opening of trading on Thursday, December 1:

Key Points: 
  • NEW YORK, Nov. 28, 2022 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the opening of trading on Thursday, December 1:
    Nexstar Media Group Inc. (NASD:NXST) will replace Sabre Corp. (NASD:SABR) in the S&P MidCap 400, and Sabre will replace Flagstar Bancorp Inc. (NYSE:FBC) in the S&P SmallCap 600.
  • S&P MidCap 400 constituent New York Community Bancorp Inc. (NYSE: NYCB) is acquiring Flagstar Bancorp in a deal expected to be completed soon pending final conditions.
  • S&P SmallCap 600 constituent PBF Energy Inc. (NYSE:PBF) will replace Nu Skin Enterprises Inc. (NYSE:NUS) in the S&P MidCap 400, and Nu Skin Enterprises will replace PBF Energy in the S&P SmallCap 600.
  • PBF is more representative of the mid-cap market space, and Nu Skin is more representative of the small-cap market space.

Nu Skin Chief Scientific Officer Dr. Joseph Y. Chang Receives Award for Outstanding Contributions in Personalized Nutrition

Retrieved on: 
Monday, November 7, 2022
Janus, Ageing, Government, American Association, Association, Doctor of Philosophy, NUS, Acquisition, Book, Arthritis, View, Growth, The New York Times, Nature, Industry, Technology, Collection, Multimedia, Therapy, American Association for the Advancement of Science, University, American Association for Laboratory Animal Science, Wellness, American Society for Pharmacology and Experimental Therapeutics, Department, NYSE, Public health, Natural product, Arthritis Foundation, Inflammation, Wyeth, Society, Health, Biotechnology, Research, Education, Skin, University of California, Davis, Management, Pharmaceutical industry, Pacific Ocean, Science, Nu Skin Enterprises, Pharmacology, University of Portsmouth

Presented by the university's Department of Nutrition, this award is given for extraordinary achievements and contributions to nutritional science.

Key Points: 
  • Presented by the university's Department of Nutrition, this award is given for extraordinary achievements and contributions to nutritional science.
  • He has 35 years of experience in the pharmaceutical and dietary supplement industries and was appointed chief scientific officer and executive vice president of product development at Nu Skin in 2006.
  • Before the acquisition of Pharmanex by Nu Skin Enterprises in 1998, Dr. Chang served as the vice president of clinical studies and pharmacology at Pharmanex.
  • Prior to Pharmanex, Dr. Chang served as president and chief scientific officer of Osteoarthritis Sciences, Inc., as well as Binary Therapeutics, Inc.

NUS Business School and Emeritus launch Chief Strategy Officer Programme to upskill senior professionals

Retrieved on: 
Thursday, November 3, 2022
Other Education, Continuing, University, Training, Education, Leadership, Research, KPMG, Curriculum, CP/M, European Quality in Social Services, Student, Industry, Graduate Management Admission Council, PIM, Head, Publication, Business school, APAC, Marine Management Organisation, COVID-19, Associate professor, Financial Times, Global strategy, CEO, Organization, Mentorship, EFMD Quality Improvement System, National university, Global Alliance in Management Education, Senior lecturer, NUS, Community, National University of Singapore, CEMS, Executive education, NUS Business School, EQUIS, GMA, Faculty, Association, University, Executive MBA Council, Management, Tutoring, Policy

The programme enables senior-level professionals to become adept in strategy formation and implementation paramount to the increasing demands of a fast-paced business world.

Key Points: 
  • The programme enables senior-level professionals to become adept in strategy formation and implementation paramount to the increasing demands of a fast-paced business world.
  • Taught by distinguished NUS Business School faculty, Andrew Delios (Professor, Strategy & Policy), Chung Yuen Kay (Associate Professor, Strategy & Policy), Lawrence Loh (Professor, Strategy & Policy), Nitin Pangarkar (Associate Professor, Strategy & Policy), and Usa Skulkerewathana (Senior Lecturer, Management & Organisation), the 9-month Chief Strategy Officer programme, in collaboration with Emeritus, is ideal for senior-level professionals, with 10+ years of work experience.
  • Commenting on the launch of the programme, Jai Arya, Head, Executive Education, NUS Business School at NUS Business School, said, The role of Chief Strategy Officer has taken on greater significance in recent times, with the growing need for businesses to keep pace with the challenges of disruption and the demands of a fast-changing marketplace.
  • The Chief Strategy Officer Programme will equip senior executives with theoretical and practical aspects of strategic leadership.